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Edited by Sandro SonninoAbstract Lysophosphatidic acid (LPA) is a lipid mediator with
multiple biological activities and is detected in various biological
ﬂuids, including human seminal plasma. Due to its cell prolif-
eration stimulatory and anti-apoptotic activities, LPA has been
implicated in the progression of some cancers such as ovarian
cancer and prostate cancer. Here, we show that prostatic acid
phosphatase, which is a non-speciﬁc phosphatase and which has
been implicated in the progression of prostate cancer, inactivates
LPA in human seminal plasma. Human seminal plasma contains
both an LPA-synthetic enzyme, lysoPLD, which converts
lysophospholipids to LPA and is responsible for LPA production
in serum, and its major substrate, lysophosphatidylcholine. In
serum, LPA accumulated during incubation at 37 C. However,
in seminal plasma, LPA did not accumulate. This discrepancy is
explained by the presence of a strong LPA-degrading activity.
Incubation of LPA with seminal plasma resulted in the disap-
pearance of LPA and an accompanying accumulation of
monoglyceride showing that LPA is degraded by phosphatase
activity present in the seminal plasma. When seminal plasma was
incubated in the presence of a phosphatase inhibitor, sodium
orthovanadate, LPA accumulated, indicating that LPA is
produced and degraded in the ﬂuid. Biochemical characterization
of the LPA-phosphatase activity identiﬁed two phosphatase
activities in human seminal plasma. By Western blotting analysis
in combination with several column chromatographies, the major
activity was revealed to be identical to prostatic acid phospha-
tase. The present study demonstrates active LPA metabolism in
seminal plasma and indicates the possible role of LPA signaling
in male sexual organs including prostate cancer.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.* Corresponding author. Fax: +81-3-3818-3173.
E-mail address: jaoki@mol.f.u-tokyo.ac.jp (J. Aoki).
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lysophospholipase D; ATX, autotaxin; PS-PLA1, phosphatidylserine-
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Lysophosphatidic acid (LPA) is a simple lipid consisting of a
phosphate, a glycerol, and a fatty acid [1,2]. In spite of its
simple structure, LPA evokes various cellular responses in
various cell types including cellular proliferation, prevention of
apoptosis, cell migration, cytokine and chemokine secretion,
platelet aggregation, smooth muscle contraction, and neurite
retraction. LPA also induces transformation and cellular
proliferation of smooth muscle cells [3]. Thus, LPA has been
implicated in certain human diseases such as arteriosclerosis [3]
and cancer cell invasion [4]. Most of these LPA actions are
mediated by G protein-coupled receptors (GPCR) that are
speciﬁc for LPA. At least four GPCRs have been identiﬁed so
far (LPA1/EDG2, LPA2/EDG4, LPA3/EDG7, and the recently
identiﬁed GPR23/p2y9/LPA4) [5]. The former three receptors
share about 50% identities with each other at the amino acid
level and form part of the endothelial diﬀerentiation gene
(EDG) family. Studies of LPA receptor-null mice suggest that
the receptors are needed for normal development [5].
LPA has been detected extracellularly in various biological
ﬂuids such as serum [6], saliva [7], follicular ﬂuid [8], hen egg
white [9] and ascites from ovarian cancer patients [10].
Among them, serum is the best characterized source of LPA
[6,11]. Two major pathways for LPA production are known
at present. LPA can be converted from pre-existing lyso-
phospholipids (LPs) [1,11] or from phosphatidic acid (PA)
generated by agonist stimulation in various types of cells [2].
We recently showed that LPA in serum is produced from
LPs such as lysophosphatidylcholine (LPC) by the action of
a plasma enzyme called lysophospholipase D (lysoPLD)
(which is also called autotaxin, ATX/NPP2) [11–13]. In ad-
dition, LPs can be supplied by multiple routes [11]. In serum
and plasma, LPC is produced from phosphatidylcholine (PC)
on lipoprotein by a plasma enzyme called lecithin-cholesterol
acyltransferase (LCAT). In activated platelets, and possibly
other types of cells, LPs are produced from the corre-
sponding diacyl phospholipids by phospholipase A-type
(PLA) enzymes, such as secretory PLA2 (sPLA2) and phos-
phatidylserine-speciﬁc PLA1 (PS-PLA1). The mechanisms of
LPA production in other biological ﬂuids (saliva and ascites)ation of European Biochemical Societies.
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ﬂuid and hen egg white, LPA may be produced from LPC
by lysoPLD activities [8,9].
Recently, we examined LPA activity in various biological
ﬂuids by measuring the LPA-induced increase in the intracel-
lular concentration of calcium ion in three types of re-
combinant Sf9 insect cells, each expressing one of the LPA
receptors [14,15]. Using this system, we found that seminal
plasma contains LPA activity that is selective speciﬁc for LPA3
[16]. LPA3 is predominantly expressed in male and female
sexual organs such as testis, prostate, uterus and oviduct
[14,17], indicating a potential role of LPA3 in reproductive
organs. In this study, which is part of a series of studies to
elucidate synthetic pathways of LPA in vivo, we attempted to
clarify the enzymes involved in the LPA production in human
seminal plasma. In the course of this study, we noticed that
seminal plasma contains strong LPA-degrading activity in
addition to LPA-producing activity. Here, we identify several
enzymes that participate actively in LPA metabolism in semi-
nal plasma.2. Materials and methods
2.1. Materials
Mouse anti-human prostatic acid phosphatase (PAP) and mouse
anti-placental alkaline phosphatase (PLAP) were purchased from
PROGEN (Brisbane, Australia) and Lab Vision Corporation (Fre-
mont, CA), respectively. 1-Oleoyl (18:1)-LPA, 1-oleoyl-LPC, and 1-
myristoyl (14:0)-LPC were purchased from Avanti Polar Lipids Inc.
(Alabaster, AL). L-Homoarginine hydrochloride was purchased from
Sigma (St. Louis, MO). Other chemicals were purchased from Wako
Pure Chemical Industries (Osaka, Japan).
2.2. Generation of lysoPLD-speciﬁc monoclonal antibodies
A polypeptide (amino acid numbers 58–182 of human ATX) was
expressed in Escherichia coli as a GST-fusion protein using the pGEX-
4T vector (Amersham Bioscience). The protein was puriﬁed using
GSH–Sepharose according to the manufacturer’s protocol. The GST-
fusion protein was used to immunize rats (WKY/Izm strain) into the
hind footpads with Freund’s complete adjuvant. The enlarged medial
iliac lymph nodes from the rats were used for cell fusion with mouse
myeloma cells, PAI. The antibody-secreting hybridoma cells were se-
lected by screening with an enzyme-linked immunosorbent assay, im-
munoﬂuorescence and Western blotting. We established three
antibody-secreting hybridoma cell lines (2A12, 3D1 and 4F1).
2.3. Western blotting
Protein samples were separated by SDS–PAGE and transferred to
nitrocellulose membranes using the Bio-Rad protein transfer system.
The membranes were blocked with Tris-buﬀered saline containing 5%
(w/v) skimmed milk and 0.05% (v/v) Tween 20, incubated with anti-
human ATX/lysoPLD monoclonal antibodies and then treated with
goat anti-rat IgG-horseradish peroxidase. Proteins bound to the an-
tibodies were visualized with an enhanced chemiluminescence kit
(ECL, Amersham Biosciences).
2.4. Preparation of various human biological ﬂuids
Blood samples were drawn from healthy volunteers (aged 22–45).
Human serum was prepared by allowing the blood to clot for 30 min at
37 C and then centrifuging it at 2000 g for 20 min at 4 C to remove
the clot. Human seminal ﬂuid, saliva, urine, sweat, and tear ﬂuid were
collected from healthy volunteers (aged 22–40). All samples were
centrifuged to remove cell components and the resulting supernatants
were immediately stored at )80 C to prevent additional formation of
LPA. Human seminal ﬂuid was kept at room temperature for 30 min
after collection. Seminal plasma was prepared by centrifuging the
seminal ﬂuid at 500 g for 10 min at 4 C to remove the sperm. Ce-
rebrospinal ﬂuid was kindly donated by Dr. Hyeun-Wook Chang(College of Pharmacy, Yeungnam University, Gyonsan, Republic of
Korea).
2.5. Quantiﬁcation of LPA and LPC
Concentrations of LPA and LPC were determined by an enzyme-
linked colorimetric method as described previously [18,19]. Glycerol 3-
phosphate (G3P) was measured by a method similar to the method for
measuring LPA as described [19]. The detection limits of our colori-
metric assay for LPA and LPC are 100 nM and 5 lM, respectively.
2.6. LysoPLD assay
LysoPLD activity was assayed with an enzyme-based colorimetric
method as described previously [12]. Brieﬂy, samples (1–50 ll) were
incubated with 2 mM 14:0-LPC in the presence of 100 mM Tris–HCl
(pH 9.0), 500 mM NaCl, 5 mM MgCl2, and 0.05% Triton X-100 for 1
h at 37 C. The liberated choline was detected by an enzymatic pho-
tometric method using choline oxidase (Asahi Chemical, Tokyo,
Japan), horseradish peroxidase (Toyobo, Osaka, Japan), and TOOS
reagent (N-ethyl-N-(2-hydroxy-3-sulfoproryl)-3-methylaniline, Dojin,
Tokyo, Japan) as a hydrogen donor.
2.7. Phosphatase assay toward LPA
Samples (1–20 ll) were incubated with 2 mM LPA (18:1) in a buﬀer
containing 100 mM Tris–HCl, pH 7.4, at 37 C for 60 min in a total
volume of 40 ll. The production of monoglyceride was determined
using Triglyceride E-test (Wako Pure Chemical Industries, Osaka,
Japan) according to the manufacturer’s protocol.
2.8. Mass spectrometry (MS)
MS spectra were obtained essentially as described previously [20]
using a Quattro Micro tandem quadrupole mass spectrometer (Mi-
cromass, Manchester, UK) equipped with an electrospray ion source
(ESI). Lipid extracts from human seminal plasma were reconstituted in
2:1 chloroform/methanol (usually 100–300 lmol/l phosphorus); 2 ll of
sample was injected per run. The samples were introduced by means of
a ﬂow injector into the ESI chamber, at the ﬂow rate of 4 ll/min. The
eluting solvent used was acetonitrile/methanol/water (2:3:1) containing
0.1% ammonium formate (pH 6.4). The mass spectrometer was oper-
ated in the positive and negative ion scan modes. The nitrogen drying
gas ﬂow rate was 12 liters/min and its temperature was 80 C. Essen-
tially, the capillary voltage was set at 3.7 kV and the cone voltage was
set at 30 V, both in the positive and negative ion modes. For MS/MS
experiments, 3–4 104 Torr of argon was used as collision gas, and a
collision energy of 30–40 V was used for obtaining fragment ions for
precursor ions.
2.9. Column chromatography
Seminal plasma (200 ll) was loaded onto a Superdex 200 gel ﬁltra-
tion column (Amersham Biosciences) and the LPA-phosphatase ac-
tivity was eluted with 100 mM Tris–HCl, pH 7.4. The pooled fractions
containing LPA-phosphatase activities (peak II in Fig. 4A) were ap-
plied to a Bioassist Q anion exchange column (TOSOH, Kanagawa,
Japan), which had been equilibrated with 100 mM Tris–HCl, pH 7.4,
and the activities were eluted with a linear gradient of NaCl (0–2 M).
Both columns were operated at 4 C using €AKTA (Amersham Bio-
sciences).3. Results
3.1. LysoPLD and LPC in human seminal plasma
To examine the mechanism underlying LPA production in
human seminal plasma, we ﬁrst tried to detect the lysoPLD that
is responsible for LPA production in serum or incubated
plasma. We found that among the various biological ﬂuids
tested, seminal plasma, cerebrospinal ﬂuid, and serum had the
highest lysoPLD activities (Fig. 1A). Unlike the serum and
plasma samples, whose lysoPLD activities varied little, the
seminal plasma samples had dramatically diﬀerent activities
(Fig. 1A). The activities were especially dependent on the in-
terval between collections of seminal ﬂuid and were propor-
Fig. 1. Both lysoPLD and LPC are detected in seminal ﬂuid. (A) LysoPLD activities of various human biological ﬂuids (cerebrospinal ﬂuid, tear,
sweat, saliva, urine, seminal ﬂuid, and serum) were determined using 14:0-LPC as a substrate. These data represent the means±S.D. of three in-
dependent samples. (B) Detection of lysoPLD protein in various human biological ﬂuids. Samples (each 5 ll) were subjected to Western blot analysis
using anti-human lysoPLD monoclonal antibody (3D1). (C) Lipids of human seminal ﬂuid were extracted by the method of Bligh & Dyer as de-
scribed under Section 2 and then subjected to lipid analysis using ESI/MS. The lipid extract was directly infused into the ESI ion source using an
Ultimate HPLC system (LC Packings) at a ﬂow rate of 4 ll/min. (D) Magniﬁcation of the positive ion spectra in the mass region m/z¼ 475–560. The
indicated molecular species were identiﬁed using tandem mass spectrometry.
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that, in seminal ﬂuid, lysoPLD is produced and released like
other proteins. Western blot analysis using the anti-human
lysoPLD monoclonal antibody established in this study con-
ﬁrmed that lysoPLD expression is high in seminal plasma
(Fig. 1B). We also examined the expression of lysoPLD in
sperm by Western blotting and found that it was expressed
weakly in the cells (data not shown). LPC, a substrate of
lysoPLD, was reported to be present in seminal plasma [21]. We
conﬁrmed the presence of LPC in human seminal plasma by
MS. The MS analysis showed that phosphatidylcholine (PC),
sphingomyeline (SM), and LPC are the major phospholipids in
seminal plasma (Fig. 1C), conﬁrming previous reports [21]. The
major LPC species, 16:0-LPC and 18:0-LPC, were detected in
seminal plasma with minor LPC components such as 18:1-
LPC, 20:1-LPC (Fig. 1D). The LPC level in seminal plasma was
found to be 8–19 lM using a recently developed enzyme-based
colorimetric method. We also examined other phospholipases
potentially involved in serum LPA production. In agreementwith a previous report [22], we detected a high level of sPLA2-
IIA in human seminal plasma (data not shown). However, we
did not detect phosphatidylserine-speciﬁc PS-PLA1 [23] nor
membrane-associated PA-selective PLA1 (mPA-PLA1) [24]
(data not shown). Thus, it is reasonable to speculate that LPA
in seminal plasma is produced from LPC by lysoPLD, as was
observed in serum and incubated plasma.3.2. Degradation of LPA in seminal plasma
LPA was found to rapidly accumulate in serum or plasma
when these samples were incubated for a long period [1,11] and
lysoPLD was found to be responsible for the LPA accumula-
tion [11]. We, therefore, tested whether LPA accumulates in
seminal plasma after a long incubation at 37 C. However,
unlike serum and plasma, seminal plasma did not accumulate
LPA (Fig. 2A). To determine whether LPA is rapidly degraded
in seminal plasma, we incubated LPA in the presence of
seminal plasma. LPA was found to rapidly degrade in the
Fig. 3. Phosphatase activity is responsible for LPA degradation in seminal ﬂuid. (A) LPA (20 lM) was incubated at 37 C in the presence or absence
of various concentrations of human seminal ﬂuid. After 30 min, LPA concentration was determined by a colorimetric assay. (B) LPA (18:1; 2 mM)
was incubated at 37 C for 1 h in the presence and absence of 0.3% (v/v) human seminal ﬂuid. The concentrations of LPA, G3P and MG were
determined by an enzyme-linked colorimetric assay as described in Section 2. These data represent the means±S.D. of three independent samples.
Fig. 2. Accumulation of LPA in incubated serum and seminal plasma. Human serum and seminal plasma were incubated at 37 C for the indicated
times (A). LPA concentrations were determined colorimetrically (see Section 2). In the case of seminal plasma, seminal plasma was incubated both in
the presence and absence of sodium orthovanadate (B).
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disappeared in 30 min when LPA was incubated with 2% (v/v)
seminal plasma at 37 C (Fig. 3A).Fig. 4. Elution proﬁles of LPA-phosphatase activity and human prostatic a
chromatography (C, D). (A, B) Human seminal plasma (200 ll) was subjec
fraction, phosphatase activity toward LPA was determined (A). Presence of
human PAP monoclonal antibodies (B). (C, D) The active fractions of gel ﬁ
subjected to Bioassist Q anion exchange column chromatography and protein
phosphatase activity toward LPA (C) and the presence of PAP (D) were de3.3. LPA is degraded by phosphatase in seminal plasma
We, thus, focused on the mechanism of LPA degradation in
seminal plasma. To know how LPA is degraded in seminalcid phosphatase on gel ﬁltration (A, B) and anion exchange column
ted to Superdex 200 gel ﬁltration column chromatography. For each
PAP was also determined by Western blot analysis using mouse anti-
ltration column chromatography (fractions 17–22 in (A)) were further
s were eluted by a linear gradient of sodium chloride. For each fraction,
termined.
Fig. 5. Biochemical characterization of two LPA-phosphatases
detected in human seminal ﬂuid (A) Heat sensitivity of the two LPA-
phosphatase activities detected in seminal plasma. Fractions contain-
ing LPA-phosphatase activities eluted from gel ﬁltration column
chromatography (peaks I and II) were heat-treated at the indicated
temperature for the indicated period. The remaining phosphatase ac-
tivities of the samples were then determined. These data represent the
means±S.D. of three independent experiments. (B) Eﬀects of several
phosphatase inhibitors on the two LPA-phosphatase activities. The
LPA-phosphatase activities of the two peaks (peaks I and II on gel
ﬁltration column chromatography) were determined in the presence of
inhibitors at the indicated concentrations. These data represent the
means±S.D. of three independent experiments.
202 M. Tanaka et al. / FEBS Letters 571 (2004) 197–204plasma, we analyzed the products of the reaction. For this
purpose, LPA was incubated in the presence of 0.3% (v/v) of
seminal plasma and LPA and possible degradation products
such as G3P and monoglyceride (MG) were analyzed by col-
orimetric assay. As shown in Fig. 3B, incubation of LPA with
seminal plasma resulted in a decrease in LPA and a concom-
itant accumulation of MG but not G3P. This clearly indicates
that LPA is degraded by phosphatase activity in seminal
plasma. We, therefore, tested the eﬀect of a phosphatase in-
hibitor on LPA accumulation in seminal plasma. We chose
orthovanadate that is often used as an inhibitor for a broad
range of phosphatases [25]. When we incubated seminal plas-
ma in the presence of 10 mM sodium orthovanadate, we did
observe an accumulation of LPA (Fig. 2B). The presence of
LPA after incubation in the presence of orthovanadate was
also conﬁrmed by a bioassay in which recombinant LPA3 ac-
tivation was evaluated by transient intracellular calcium mo-
bilization (data not shown). Thus, we conclude that
phosphatase activity is responsible for LPA degradation in
seminal plasma and that LPA is actually produced and de-
graded in seminal plasma.
3.4. Biochemical characterization of LPA-phosphatase in
seminal plasma
To identify the phosphatase activity toward LPA, we next
biochemically characterized the LPA-phosphatase in seminal
plasma. Seminal plasma was subjected to gel ﬁltration chro-
matography and the fractions were assayed for LPA phospha-
tase activity. One major peak (Fig. 4A, peak II) and one minor
peak (peak I) were obtained, with estimated molecular weights
of 150 kDa and 650 kDa, respectively. The activity of the major
peak was highest in the pH range 4–7 (data not shown).
In seminal plasma, several isoforms of phosphatase have
been detected and identiﬁed. Western blot analysis using a
monoclonal antibody against human PAP [26] detected a 55-
kDa band that co-migrated with LPA-phosphatase activity on
both the gel ﬁltration column (Fig. 4A and B) and a Bioassist
Q column (Fig. 4C and D). This indicates that PAP is the
major phosphatase that degrades LPA in human seminal
plasma. Neither the anti-PAP antibody nor a monoclonal
antibody against PLAP [27] reacted with the minor phospha-
tase peak (peak I in Fig. 4A) (data not shown).
Alkaline phosphatase (AP, EC 3.1.3.1), an enzyme which
catalyzes hydrolysis of organic phosphate at basic pH values,
has been reported in human seminal ﬂuid [28]. Four APs, each
encoded by a diﬀerent gene, have been identiﬁed [28]. These
APs (tissue non-speciﬁc, intestinal, placental, and placental-like
AP) can be distinguished by their sensitivities to heat and
certain L-amino acids. Heating is reported to destroy non-
placental enzymes, while leaving placental and placental-like
enzymes essentially unaﬀected [28]. Heat treatment (for 15 min
at 56 C or for 10 min at 65 C) reduced the LPA-phosphatase
activity of peak I by only 25–30% while it nearly abolished the
activity of peak II (Fig. 5A). L-Phenylalanine and L-leucine are
reported to inhibit the intestinal, placental and placental-like
isoenzymes [25]. L-Homoarginine is reported to inhibit the
tissue non-speciﬁc isoenzymes [25]. While L-leucine signiﬁ-
cantly reduced the phosphatase activity of peak I by 75%, L-
phenylalanine and L-homoarginine did not markedly reduce
the phosphatase activity of both peaks (Fig. 5B). Tartrate,
which is an eﬀective inhibitor of PAP [29], markedly reduced
the phosphatase activity values of both peaks (Fig. 5B). Thephosphatase activity of peak II was more sensitive to EDTA
than that of peak I (Fig. 5B). The diﬀerent temperature, leucine
and EDTA sensitivities of the two LPA-phosphatase activities
indicate that these activities are due to diﬀerent isozymes. And
the fact that the sensitivities of peak I activity are not consistent
with those of any of the four known APs indicates that the peak
I activity is due to a novel phosphatase isozyme.
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4.1. LysoPLD is involved in LPA production in various
biological ﬂuids including seminal plasma
We previously showed that serum LPA is produced from
LPs such as LPC by the action of a plasma enzyme called
lysoPLD [11]. Interestingly, lysoPLD is identical to a cell
motility-stimulating factor, ATX [12,13]. ATX has been im-
plicated in cancer invasion and metastasis, because it is
sometimes overexpressed in various cancer tissues [30]. The
present study was undertaken as continuing studies to examine
a role of lysoPLD/ATX in LPA production in vivo. Our
Western blot analysis demonstrated that lysoPLD/ATX is
widely distributed in various biological ﬂuids such as cere-
brospinal ﬂuid and seminal plasma in addition to serum
(Fig. 1B). Interestingly, LPC, a major substrate of lysoPLD/
ATX, was detected in these biological ﬂuids (Fig. 1C and D).
Thus, lysoPLD/ATX may be involved in LPA production in
various biological ﬂuids other than serum and plasma. It is
particularly interesting to note that the expression of lysoPLD/
ATX is extremely high in seminal plasma (Fig. 1A and B). We
previously showed that LPA is present in seminal plasma,
because seminal plasma induces transient [Ca2þ]i in LPA3-
expressing insect Sf9 cells [16]. We detected LPC in seminal
plasma (Fig. 1C and D), but hardly detected LPA by our en-
zymatic colorimetric assay (Fig. 2A). The minimum concen-
trations of LPA in our colorimetric assay and bioassay for
LPA-detecting system are 100 and 10 nM, respectively.
This explains why we could detect LPA-activity only by
bioassay.4.2. Active LPA metabolism in seminal plasma
The LPA level in seminal plasma was low, but increased
when seminal plasma was incubated in the presence of so-
dium orthovanadate, a classical phosphatase inhibitor
(Fig. 2B). The level of choline, a reaction product of lysoPLD
from LPC, in seminal plasma is extremely high (mM order)
[31]. Strong phosphatase activity against LPA was detected in
seminal plasma (Fig. 3A). All these results support the hy-
pothesis that LPA is continuously produced and degraded in
seminal plasma. Because the major LPC species in seminal
plasma were 16:0- and 18:0-LPC (Fig. 1D), PLA2 may be
responsible for the LPC production in seminal plasma. We
detected PC (Fig. 1C) and sPLA2IIA (data not shown) in
seminal plasma, which could be potential sources of LPC in
seminal plasma.4.3. Potential role of LPA in seminal plasma
Seminal ﬂuid is derived from at least three organs; prostate,
seminal vesicle and testis. Fluids from each organ are mixed
just before the ejaculation. It is clear that PAP is derived from
the prostate [29], while it has not been determined where
lysoPLD and LPC are derived from mRNA of lysoPLD/ATX
is detected both in prostate and testis in both humans and
mice, indicating that these organs are potential sources of
lysoPLD/ATX. Interestingly, lysoPLD activity, LPC content
and LPA-phosphatase activity diﬀer in various samples. It
should be noted that lysoPLD activity in seminal plasma from
same individuals is dependent on the intervals between sem-
inal ﬂuid collections (data not shown). In addition, the ratios
of LPC and lysoPLD diﬀer among the samples. These resultsindicate that lysoPLD and LPC are derived from diﬀerent
organs.
The physiological role of LPA in seminal ﬂuid is not known.
So far, at least four LPA receptors have been identiﬁed and
characterized [5]. These LPA receptors are highly expressed in
several male sexual organs such as testis and prostate and in
female sexual organs such as uterus, oviduct and ovary. LPA
in seminal ﬂuid may have a role in such male organs. In ad-
dition, it may have a role in female organs such as uterus and
oviduct after semen is ejaculated. Interestingly, Kunikata et al.
[32] reported that LPA stimulates mouse ovum transport by
contracting oviductual smooth muscle mediated by a pertussus
toxin-sensitive GPCR, possibly LPA1–4. Recently, Yue et al.
[33] demonstrated that mice with transgenic overexpression of
one isoform of an LPA-degradation enzyme, lipid phosphate
phosphatase-1 (LPP-1), display multiple organotypic deﬁcits
including abnormal testis development that results in a se-
verely impaired spermatogenesis. This also implies that LPA
has a role in signaling in sexual organs.
4.4. Potential role of PAP in prostate and prostate cancer
LPA has been shown to induce the growth and survival of
cancer cells [4]. Thus, LPA has been implicated in cancer cell
development, especially in prostate cancer cells [34,35]. Ex-
pression of LPA receptors (LPA1, LPA2 and LPA3) and
LPA-producing enzymes (lysoPLD and mPA-PLA1) has
been observed in prostate cells or prostate cancer cells. PAP
(EC 3.1.3.2) is a non-speciﬁc phosphomonoesterase that is
synthesized and secreted into seminal plasma under andro-
genic control [29]. The enzyme is a dimer of molecular
weight around 100 kDa. PAP was formerly used as a marker
for diagnosis and therapy control of prostate cancer [29].
However, its role as a prostate cancer marker has now been
taken over by prostate-speciﬁc antigen. In this study, we
identiﬁed PAP as the main LPA-phosphatase in seminal
plasma, although a less active phosphatase was also detected
(Fig. 4). The estimated molecular weight, heat stability, and
inhibitory patterns by several phosphatase inhibitors of the
minor phosphatase (Fig. 5) indicate that it is a novel phos-
phatase speciﬁc to LPA, which should be identiﬁed in further
studies.
Lipid phosphate such as PA, ceramide 1-phosphate (C1P),
sphingosine 1-phosphate (S1P) and LPA can be substrates for
a family of enzymes called LPPs [36]. The LPPs can dramati-
cally alter the balance between phosphate esters and their
dephosphorylated products [36]. The LPPs are integral mem-
brane proteins and the ‘‘ecto-activity’’ of the LPPs negatively
regulates the extracellular actions of LPA and S1P [36]. We
propose here that soluble enzymes also participate in regulat-
ing the extracellular actions of lipid phosphates and that PAP
is one candidate for a degrading enzyme. It has been demon-
strated that human prostate cancer cells show a decreased level
of expression of the cellular form of the enzyme [37]. Several
lines of evidence indicate that cellular PAP is critical for reg-
ulating proliferation and androgen responsiveness of human
prostate cancer cells: (i) LNCaP cells that express cellular PAP
have a slow growth rate, compared with PC-3 and DU-145
cells that lack endogenous PAP expression [38]. (ii) Introduc-
tion of cellular PAP into prostate cancer cells results in a de-
creased growth rate [38]. (iii) The cellular form of PAP is also
involved in regulating the androgen-stimulated growth of
prostate cells [39]. C-33 LNCaP cells that express PAP and
204 M. Tanaka et al. / FEBS Letters 571 (2004) 197–204androgen receptor are responsive to androgen stimulation,
whereas C-81 LNCaP and PC-3 prostate carcinoma cells that
express functional androgen receptor but lack PAP expression
are androgen-unresponsive. (iv) Androgen responsiveness of
these cell lines can be restored by reintroducing cellular PAP
expression [39]. Thus, we propose that PAP has a role in in-
hibiting the proliferation of prostate cells by negatively regu-
lating the LPA level. The lower expression of PAP in prostate
cancer may result in constitutive activation of LPA receptors
and lead to the progression of prostate cancer. Further studies
are needed to prove this hypothesis.
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